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ABSTRACT: Phosphodiesterase (PDE) 7 is involved in pro-inflammatory processes 
being widely expressed both on lymphocytes and on certain brain regions. Specific 
inhibitors of PDE7 have been recently reported as potential new drugs for the treatment 
of neurological disorders due to their ability to increase intracellular levels of cAMP 
and thus, modulating the inflammatory process, as a neuroprotective well-established 
strategy. Multiple sclerosis is an unmet disease in which pathologies on inmunitary 
system, T-cells, and specific neural cells are involved simultaneously. Therefore, PDE7 
inhibitors able to interfere with all these targets may represent an innovative therapy for 
this pathology. 
Here, we report a new chemically diverse family of heterocyclic PDE7 inhibitors, 
discovered and optimized by using molecular modeling studies, able to increase cAMP 
levels in cells, decrease inflammatory activation on primary neural cultures and also 
attenuate the clinical symptoms in the experimental autoimmune encephalomyelitis 
(EAE) mouse model. These results led us to propose the use of PDE7 inhibitors as 
innovative therapeutic agents for the treatment of multiple sclerosis. 
 
 
Keywords: PDE7 inhibitors, multiple sclerosis, drug design, docking studies 
 
Abbreviations: ADME, Absorption, Distribution, Metabolism and Excretion; BBB, 
blood-brain barrier; cAMP, cyclic adenosine 3’,5’-monophosphate; CFA, complete 
Freund’s adjuvant; cGMP, cyclic guanosine 3’,5’-monophosphate; CNS, central 
nervous system; DCC, N,N'-dicyclohexylcarbodiimide; DMEM, Dulbecco's modified 
Eagle's medium; DMSO, dimethyl sulfoxide; EAE, experimental autoimmune 
encephalomyelitis; EDTA, ethylenediaminetetraacetic acid; ES, electrospray; FBS, fetal 
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bovine serum; FP, fluorescence polarisation; GFAP, glial fibrillary acidic protein; GM-
CSF, granulocyte-macrophage colony-stimulating factor; HAMS, Ham’s F-12 nutrient 
mixture; HBSS, Hank's balanced salt solution; IC50, inhibitory concentration 50; IMAP, 
Immobilized Metal Ion Affinity-Based Fluorescence Polarization, MOG, myelin 
oligodendrocyte glycoprotein; mRNA, messenger ribonucleic acid; MS, mass 
spectrometry; MTT, 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide; 
NMR, Nuclear magnetic resonance; LPS, lipopolysaccharide; PAMPA, parallel 
artificial membrane permeability assay; PBL, porcine polar brain lipid; PBS, Phosphate 
Buffer Saline; PDEs, phosphodiesterases; PDVF, polyvinylidene difluouride; PyBOP, 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate; SAR, structure 
biological activity relationships; SD, standard deviation; SDS, sodium dodecyl sulfate; 
SPA, Scintillation Proximity Assay; TEA, triethylamine; THF, tetrahydrofuran; UV, 
ultra-violet light. 
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INTRODUCTION 
The nucleotides cyclic adenosine 3’,5’-monophosphate (cAMP) and cyclic guanosine 
3’,5’-monophosphate (cGMP) are two ubiquitous second messengers that mediate a 
variety of cellular responses. Two enzymatic processes control the intracellular levels of 
these nucleotides: the first one by regulation of their synthesis, achieved through the 
action of adenylate or guanylate cyclase, and the second one through their hydrolysis 
catalyzed by phosphodiesterases (PDEs).1 Up to now there are 11 known families of 
PDEs that control the levels of cAMP and cGMP by catalyzing their hydrolysis to AMP 
or GMP, respectively. The family members are classified according to their sequence 
identity, cellular distribution, substrate specificity, and sensitivity to different PDE 
inhibitors,2, 3 being good targets for pharmacological intervention. In fact, one of the 
greatest advances in the PDE field in the last 15 years has been the increased 
availability and more recently the clinical use of family-selective inhibitors.4 Therefore, 
PDE inhibitors may have considerable therapeutic utility as anti-inflammatory agents, 
antiasthmatics, vasodilators, smooth muscle relaxants, cardiotonic agents, 
antidepressants, antithrombotics, and agents for improving memory and other cognitive 
functions.5 The members of the PDE superfamily are well placed to be targets for 
pharmacological intervention. As elevation of intracellular cAMP level shows 
immunosuppressive and anti-inflammatory properties,1, 6 selective inhibitors of cAMP-
specific PDEs have been widely studied as therapeutic agents for the treatment of 
human diseases.5 The PDEs responsible for controlling specifically the intracellular 
levels of this nucleotide are PDE4, PDE7 and PDE8. More information is known about 
PDE4 being involved in the hydrolysis of cAMP within immune and central nervous 
system (CNS) cells. Thus, PDE4 inhibitors have been widely studied as efficient anti-
inflammatory agents for different diseases.7 However, a major drawback of these 
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compounds is the significant emetic effects. To overcome these adverse effects, several 
strategies have been developed.8 An alternative approach is to target different cAMP 
specific PDEs families as PDE79 expressed also in T-cells and CNS and being a good 
target for the control of neuroinflammation.10 
The PDE7 family is composed of two genes, PDE7A and PDE7B. High mRNA 
concentrations of both PDE7A and PDE7B are expressed in rat brain and in numerous 
peripheral tissues, although the distribution of these enzymes at the protein levels has 
not been reported. Within the brain PDE7A mRNA is abundant in the olfactory bulb, 
hippocampus, and several brain-stem nuclei.11 The highest concentrations of PDE7B 
transcripts in the brain are found in the cerebellum, dentate gyrus of the hippocampus 
and striatum.12, 13 There is very little information regarding the physiological functions 
regulated by PDE7. It has been shown that PDE7 is involved in pro-inflammatory 
processes and is necessary for the induction of T-cell proliferation.14 Specific inhibitors 
of PDE7 have been recently reported as potential new drugs for the treatment of 
neurological disorders15 by modulation of the inflammation process, a well-established 
neuroprotective strategy. Moreover, multiple sclerosis involved simultaneously 
pathologies on inmunitary system, T-cells, and specific neural cells, such as microglia 
and oligodendrocytes. Current pharmacological treatments for multiple sclerosis have 
severe drawbacks such as lack of efficacy and pharmacokinetics properties, being the 
search for new treatments and attractive field of research. PDE7 inhibitors may 
represent a well targeted and innovative therapy for this pathology.  
Several years ago, our research group was the first one in reporting the first PDE7 
selective inhibitors.16 Since then, a lot of efforts have been done to increase potency and 
selectivity of this kind of compounds, conforming a great variety of diverse chemical 
compounds with interesting pharmacological profiles.17  
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Following our on-going research on this field, we have recently demonstrated that 
PDE7 inhibitors belonging to the quinazoline family enhance neuroprotection and 
decrease neuroinflammation in well-characterized cellular and animal models of 
Parkinson’s disease,18 spinal cord injury,19 and stroke.20  
With the aim to design potent and specific PDE7 inhibitors, we developed a 
pharmacophore model for PDE7A1 inhibitors using Catalyst/Hypogen program to 
identify the chemical features that are responsible for the inhibitory activity.21 Four 
pharmacophore features, such as one hydrogen bond acceptor, one aromatic ring and 
two hydrophobic aliphatic points were identified to be involved in inhibitor-PDE7 
interaction (Chart 1). This pharmacophore model was able to predict the activity of 
external test set of PDE7 inhibitors with a correlation coefficient of 0.96. New leads 
identification was carried out by performing virtual screening using validated 
pharmacophoric queries and four chemical databases (Maybridge, Chemical Diversity, 
Specs and National Cancer Institute). Further data reduction was done employing 
virtual filters based on distances (T=1.5Å), angles (10º) and Lipinski’s rules of five. 
According to this procedure, three new hits (1-3) were found as potential PDE7A1 
inhibitors structurally diverse from those previously known22 (Table 1). Then, the 
biological activity of the hits was calculated using the catalytic domain of PDE7A1 and 
a radiometric assay. 
 
Here, Chart 1 
 
Here, Table 1 
 
Page 6 of 48
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
These three hits were selected for further medicinal chemistry programs aimed to 
increase not only efficacy but also the ADME profile to be considered for further drug 
development in the neurodegenerative field. Here, the results obtained in the 
development of the family derived from the furan 1 and its therapeutic potential for 
multiple sclerosis are reported. 
RESULTS AND DISCUSSION 
Chemistry. The 5-(2-methyl-4-nitrophenyl)-2-furylmethyl 3,4,5-triethoxybenzoate 
(1) has a furan heterocycle between two substituted phenyl rings moieties. In particular, 
the structural modifications proposed are based on the modification of the number and 
nature of substituents attached to both phenyl rings and the variation of the linker 
between the furan and the alkyloxyphenyl ring (Chart 2). 
 
Here, Chart 2 
 
The synthetic routes for the preparation of the furan derivatives are summarized in 
Schemes 1 and 2. The 5-phenyl-2-furylmethyl benzoate derivatives (Scheme 1) were 
obtained in one synthetic step, after the coupling reaction of the alkyloxybenzoic acid 
and the corresponding 5-phenyl-2-furylmethanol. These furan alcohols were 
commercial available with the only exception of 5-(2,4-dichlorophenyl)-2-
furylmethanol (4) which was synthesized by reduction of the 5-(2,4-dichlorophenyl)-2-
furoic acid with lithium aluminum hydride as described in the supporting information. 
 
Here, Scheme 1 
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The synthesis of benzyl 5-phenylfuroate and benzyl 5-phenylfuramide derivatives 
(Scheme 2) involved the coupling of alkyloxybenzyl alcohol or alkyloxybenzyl amine 
with the furoic acid derivative. Among different coupling reagents previously used, 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) was 
chosen as the most convenient one.  
The structures of all the synthesized products were unequivocally confirmed by mass 
spectrometry, elemental analysis, and 1H and 13C NMR spectroscopic data. 
 
Here, Scheme 2 
 
In vitro evaluation of PDE7 inhibition. The new derivatives here synthetized (5-32) 
were tested for their inhibitory potencies against PDE7A1 using recombinant human 
isoenzyme as described in the experimental section. All the compounds were tested at a 
fixed concentration (10 µM) by duplicate. The percentage of inhibition obtained on 
PDE7A1 for all the compounds at this concentration is showed in Table 2. From these 
data we can conclude that several new compounds are inhibitors of PDE7A1.  
 
Here, Table 2 
 
As the biological assay conditions differs from that previously used,22 the lead 
compound 1 was also here evaluated to compare the data with the new synthesized 
derivatives. Noteworthy is the fact that when the lead compound 1 was evaluated in the 
new experimental conditions using the complete enzyme instead of the catalytic domain 
of PDE7A1, only a 29% of PDE7A1 inhibition at 10 µM was found. Regarding this 
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new data, modifications performed on the chemical structure of 1 increase in general the 
inhibition of PDE7A1.  
When the percentage of PDE7A1 inhibition was greater than 50%, the dose response 
curve was determined and the IC50 values calculated (Table 3). Some of these new 
compounds present IC50 values regarding PDE7A1 inhibition in the low micromolar 
range being suitable candidates to be further explored. A kinetic study varying cAMP 
concentration was performed with two of these compounds (13 and 31) to better 
characterize the enzymatic inhibition. Double-reciprocal plotting of the data is depicted 
in figure 1. The intercept of the plot in the horizontal axis (1/[cAMP]) changes when the 
compound 13 and 31 concentrations increase, whereas the intercept in the vertical axis 
(1/V) does not change. These results suggest that furan derivatives act as competitive 
inhibitors of cAMP binding site and allow us to determine the Ki of these inhibitors, 
(5.91 and 7.22) for compounds 13 and 31 respectively. 
 
Here, Table 3 
Here, Figure 1 
 
Docking studies. In order to gain some insight in the binding mode of our family of 
compounds, docking experiments were carried out with help of Surflex method 
implemented in Sybyl according to the procedure described in the experimental section. 
Considering the kinetic studies results, the docking studies were focused on the cAMP 
binding site. After careful examination of docking solutions two binding modes that can 
draw the chemical structure biological activity relationships (SAR) in this serie of 
compounds were proposed. In fact, the different substituents and their location (ortho, 
meta or para) when R3 is a phenyl ring, determine which binding mode is selected.  
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The mainly binding mode (namely “A” from now) is characterized by a hydrophobic 
interaction of the phenyl group in R3 with Val380 and a NH-π interaction23, 24 with 
Gln413, which is in fact, a conserved residue among PDEs families.25 A clearly 
example of this binding mode is compound 13 (see figure 2). In addition to these 
interactions, the furan moiety contributes to increase inhibition by means of a stacking 
interaction with another conserved residue as Phe416. Furthermore, the 3,4,5-
trimethoxy-phenyl ligand’s moiety is located in a pocket where the ligand can take 
benefit of a hydrogen bond between the methoxy group in R2 and the proton Hε of 
His256 group (dHε…O = 2.7Å) and a hydrophobic interaction with Phe384. 
 
Here, Figure 2 
 
When R1 and R2 are ethoxy groups (compound 24), the binding mode remains mode 
“A”, (see figure 3). The presence of these bigger substituents forces the ligand to 
reorient the ester group keeping a hydrophobic interaction with Phe384. This new 
location causes a weakening of the parallel stacking interaction between the furan ring 
and Phe416 (found for compound 13) because of the displacement of the furan ring in 
order to keep the hydrophobic interaction between ligand’s benzene ring in R3 and 
Val380. As a result, compound 24 shows a lower percentage of PDE7A1 inhibition than 
compound 13 (table 2). 
 
Here, Figure 3 
 
Regarding the substituent located in para position in the phenyl attached in R3 such a 
methyl group (compound 23), the ligand orients this substituent facing it towards the 
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Leu401 adopting thus the binding mode “B” (see figure 4). This new orientation avoids 
potential steric clashes and allows the establishment of a new hydrophobic interaction 
between the methyl group and the side chain of Leu401 meanwhile the previous 
stacking between the furan and Phe416 is mostly conserved. Furthermore, this new 
orientation forces the second phenyl ring to a new position where two new interactions 
with Ile323 are established which can help to stabilize the ligand in this new binding 
mode. 
 
Here, Figure 4 
 
Finally, when the ester group linker is replaced by an amide one, (compounds 30-
32), the conformation of the ligands dramatically changes by the formation of an intra-
molecular hydrogen bond between NH group and furan’s oxygen. This conformation 
allows new stabilizing interactions between the phenyl ring with Leu401’s side chain 
where it can interact hydrophobically (Figure 5).  
 
Here, Figure 5 
 
In vitro antiinflamatory studies. Our next step was to explore whether these new 
PDE7 inhibitors are able to reduce the inflammatory response in different cell based 
assays. Thus, we used primary cultures of astrocytes and microglia treated with 
lipopolysaccharide (LPS), a potent inflammatory agent. 
The potential anti-inflammatory activity of the selected PDE7 inhibitors (7, 13, 14, 
19 and 31) was measured by evaluating the production of nitrites from primary cultured 
glial cells (astrocytes and microglia). To asses the safety of the compounds on cell 
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culture, the astrocytes and microglia viability were checked using the 3-[4, 5-
dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) test at two different 
concentrations of the compounds. As both concentrations used do not affect the cell 
survival, they were selected for the antiinflammatory experiment.  
Cultures were incubated with the indicated concentrations of the compounds 7, 13, 
14, 19, 21 and 31 for 1 h, and then cells were treated for 24 h with LPS. When primary 
astrocytes and microglial cells were stimulated with LPS (Figures 6 and 7) a significant 
induction of nitrite production in the culture medium, was produced, while if the PDE7 
inhibitors were in the medium a significant decrease of nitrite production was observed 
as a consequence of a reduction of the inflamatory cell response by the drug treatment. 
We used as standard references the well known PDE4 inhibitor Rolipram and the PDE7 
inhibitor BRL50481.26 These compounds showed a neuroprotective effect which was in 
accordance with our previously reported results,20 confirming that these cell permeable 
PDE7 inhibitors are able to decrease neural inflammatory activation.  
 
Here, Figure 6 
 
Here, Figure 7 
 
Candidate selection for in vivo studies. The final aim of our study was to proof the 
potential efficacy of these new PDE7 inhibitors in a multiple sclerosis murine model. 
The selection of the candidate for in vivo studies was done based on pharmacological 
and pharmacokinetic properties. 
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Recently, potential cardiotoxic effect of long-term PDE3A inhibition was reported.27 
Thus, to avoid adverse effects in further development steps we measured the inhibition 
on PDE3A of our selected compounds (Table 4). 
 
Here, Table 4 
 
Considering these new data, almost every derivative tested inhibit PDE3A at the 
same concentration that PDE7A1 was also inhibited, showing a lack of selectivity and 
opening safety concerns in further pharmacological development. However, derivative 
13 shows an IC50 value tenfold higher on PDE3A regarding PDE7A1 (ratio 
PDE7A1/PDE3A=0.09), selecting this candidate for the next studies.  
To evaluate isoenzyme specificity of 13, inhibition of different cAMP isoenzymes 
was determined (Table 5). While marginal inhibition was found on PDE4B2, no activity 
was found on PDE7B and PDE4D3. The partial inhibition of PDE4B2 may increase the 
biological action of 13 in vivo because cAMP levels might be enhanced. Moreover, it is 
worth mentioning that inhibition of PDE4D3 is associated to the adverse emetic effects 
in the development of PDE4 inhibitors.28 As derivative 13 does not inhibit this specific 
isoenzyme, its safety potential regarding PDEs inhibition is reinforced.  
 
Here, Table 5 
 
We also check the ability of derivative 13 to regulate intracellular cAMP levels in 
cell cultures. Two different compound concentrations (10 and 30 µM) were used and in 
both cases we observed an increase of cAMP even more effective than the reported 
PDE7 inhibitor BRL5048126 (Figure 8). 
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 Here, Figure 8 
 
Finally, and to decipher if this compound has the drug profile to be administered in 
vivo, we determined its ability to cross the blood-brain barrier (BBB), one of the major 
obstacles for the treatment of diseases in the central nervous system. The majority of 
compounds enter the brain by transcellular passive diffusion, which is driven by a 
concentration gradient between the blood and the brain.29 Parallel Artificial Membrane 
Permeability Assay (PAMPA) is a high throughput technique developed to predict 
passive permeability through biological membranes. Here, we used the PAMPA-BBB 
method described by Di et al.30 employing a brain lipid porcine membrane, to determine 
the ability of compound 13 to penetrate into the brain. The in vitro permeabilities (Pe) 
of commercial drugs through lipid membrane extract together with compound 13, were 
determined and described. A good correlation between experimental and described 
values Pe (exp)= 1.1512 (bibl) - 0.8973 (R2= 0.9779) was obtained (see supporting 
information). From this equation, the Pe (exp) for 13 is (8.1 ± 0.1)10-6 cm s-1. Following 
the pattern established in the literature for BBB permeation prediction31 that classify 
compounds as CNS + when they present a permeability > 3.71 x 10-6 cm s-1, we can 
consider that compound 13 is able to cross the BBB by passive permeation.  
In vivo studies. Experimental autoimmune encephalomyelitis model. The results 
found in cell cultures for the new PDE7 inhibitor 13 together with their ability to cross 
the BBB, prompted us to evaluate it in chronic experimental autoimmune 
encephalomyelitis (EAE) mice, a well establish murine model for multiple sclerosis.  
EAE was induced in C57BL/6J mice by immunization with MOG35-55 in complete 
Freund’s adjuvant on day 0. Clinical signs and score were monitored up to day 41. Mice 
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began to show neurological deficits on day 12, reaching a maximum score around day 
16. A therapeutic regimen of administration was chosen to test the PDE7 inhibitor in the 
EAE model. Thus a daily i.p. administration of compound 13 for 26 days started at day 
5 after disease onset. The dose was selected considering the IC50 value on the target and 
the cellular anti-inflammatory activity. As we can see in figure 9A, a clear and 
significant attenuation of clinical symptoms during the first 16 days of treatment (day 
32 after immunization figure 9A) was observed. However, this behavior is lost in the 
last ten days of treatment. The body weight curve (Figure 9B), reflects these findings 
and the compound 13-treated mice start to lose weight in the same frame-time than 
clinical scores decrease (described above). 
This experiment showed for the first time efficacy of PDE inhibitors on a well 
established model of multiple sclerosis. Compound 13 administrated to the EAE when 
the worst neurological score was measured, showed a recovery of the clinical symptoms 
reaching a statistically significant plateau of maximum effect from day 21 to 31 p.i. 
However, this attenuation of the symptoms was counterbalanced by the worsening of 
the animals during the last 10 days of treatment until day 42, when the animals were 
sacrificed. To decipher if this effect is due to the administrated compound (stability, 
metabolism, etc) or to the animal model further studies are in progress. 
 
Here, Figure 9 
 
CONCLUSIONS 
PDE7 inhibitors represent a new class of innovative drugs with great potential for 
several neurological disorders. Their efficacy in animal models of Parkinson disease, 
stroke, and spinal cord injury has been recently reported while their value for the 
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treatment of multiple sclerosis is here disclosed. We presented the medicinal chemistry 
program around one hit found by using a pharmacophore model. The work lead to a 
novel serie of PDE7 inhibitors, chemically diverse from those known and containing a 
furan ring in their chemical structure.  
The biological profile has been well characterized showing an increase of cAMP 
level and a reduction of the inflammatory response in primary neural cell cultures. 
Moreover, a clear strategy to select the best compound for in vivo testing, using 
pharmacodynamic and pharmacokinetic criteria was followed. Finally, compound 13 
was chosen due to its PDE7 selectivity and its ability to cross the BBB. This compound 
is able to reverse clinical symptoms in an EAE mice model. All together these data 
supported the potential of PDE7 inhibitors for the therapeutic pharmacological 
treatment of multiple sclerosis. 
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EXPERIMENTAL 
 
Chemical procedures. Substrates were purchased from commercial sources and 
used without further purification. Melting points were determined with a Mettler Toledo 
MP70 apparatus. Flash column chromatography was carried out at medium pressure 
using silica gel (E. Merck, Grade 60, particle size 0.040-0.063 mm, 230-240 mesh 
ASTM) with the indicated solvent as eluent. Compounds were detected with UV light 
(254 nm). 1H NMR spectra were obtained on the Bruker AVANCE-300 spectrometer 
working at 300 MHz or on a Varian INOVA 400 spectrometer working at 400 MHz. 
Typical spectral parameters: spectral width 10 ppm, pulse width 9 μs (57°), data size 32 
K. 13C NMR experiments were carried out on the Bruker AVANCE-300 spectrometer 
operating at 75 MHz or on a Varian INOVA 400 spectrometer working at 100 MHz. 
The acquisition parameters: spectral width 16 kHz, acquisition time 0.99 s, pulse width 
9 μs (57°), data size 32 K. Chemical shifts are reported in values (ppm) relative to 
internal Me4Si and J values are reported in Hz. Elemental analyses were performed by 
the analytical department at CENQUIOR (CSIC), and the results obtained were within ± 
0.4% of the theoretical values.  
5-(4-Phenyl)-2-furylmethyl 3,4,5-triethoxybenzoate (7). PyBOP (358 mg, 0.68 
mmol) was added as coupling reagent to a solution of 3,4,5-triethoxybenzoic acid (175 
mg, 0.68 mmol) with TEA (158 µL, 1.15 mmol) in CH2Cl2 (10 mL) followed by 5-
phenyl-2-furylmethanol (100 mg, 0.57 mmol), and the resulting mixture was stirred at 
25 ºC during 12 hours. The reaction mixture was evaporated in vacuo and the solid was 
purified by column cromatography on silica using hexane/ethyl acetate (8:1) as eluent to 
afford a yellow solid (246 mg, 87% yield). mp 71.1 ºC. 1H NMR (300 MHz, CDCl3): δ 
7.70-7.29, 6.64, 6.56, 5.33, 4.10, 1.42, 1.35. 13C NMR (75 MHz, CDCl3): δ 166.5, 
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153.0, 149.5, 149.1, 129.2, 125.7, 128.1, 125.7, 124.3, 124.4, 113.7, 108.8, 106.3, 69.4, 
65.2, 59.2, 16.0, 15.2. MS (ES, [M+K]+): m/ z = 449. Anal. C25H28O5 (C, H, O). 
3,4,5-Trimethoxybenzyl 5-phenyl-2-furoate (13). PyBOP (639 mg, 1.23 mmol) was 
added as coupling reagent to a solution of 5-phenyl-2-furoic acid (200 mg, 1.03 mmol) 
with TEA (284 µL, 2.06 mmol) in CH2Cl2 (10 mL) followed by 3,4,5-trimethoxybenzyl 
alcohol (210 µL, 1.27 mmol), and the resulting mixture was stirred at 25 ºC during 23 
hours. The reaction mixture was evaporated in vacuo and the solid was purified by 
column cromatography on silica using hexane/ethyl acetate (8:1) as eluent to afford a 
white solid (90 mg, 24% yield). mp 98.4 ºC. 1H NMR (300 MHz, CDCl3): δ 7.79, 7.45-
7.26, 6.69, 5.29, 3.93-3.85. 13C NMR (75 MHz, CDCl3): δ 159.0, 158.2, 153.7, 143.9, 
138.5, 131.7, 129.8, 129.4, 129.2, 125.3, 120.7, 107.3, 106.1, 67.1, 61.2, 56.6. MS (ES, 
[M+Na]+): m/ z = 391. Anal. C21H20O6 (C, H, O). 
3,4,5-Trimethoxybenzyl 5-(2-trifluoromethylphenyl)-2-furoate (14). PyBOP (393 
mg, 0.76 mmol) was added as coupling reagent to a solution of 5-(2-
trifluoromethylphenyl)-2-furoic acid (200 mg, 0.76 mmol) with TEA (174 µL, 1.26 
mmol) in CH2Cl2 (10 mL) followed by 3,4,5-trimethoxybenzyl alcohol (129 µL, 0.65 
mmol), and the resulting mixture was stirred at 25 ºC during 12 hours. The reaction 
mixture was evaporated in vacuo and the solid was purified by column cromatography 
on silica using hexane/ethyl acetate (6:1) as eluent to afford a white solid (123 mg, 36% 
yield). mp 89.8 ºC. 1H NMR (300 MHz, CDCl3): δ 7.80, 7.68, 7.53, 7.30, 6.79, 6.69, 
5.30, 3.89, 3.86. 13C NMR (75 MHz, CDCl3): δ 158.8, 154.5, 153.7, 144.8, 138.5, 
132.3, 131.6, 131.1, 129.5, 128.8, 127.3, 124.1, 120.2, 112.4, 106.1, 67.2, 61.3, 56.5. 
MS (ES, [M+Na]+): m/ z = 459. Anal. C22H19F3O6 (C, H, O). 
3,4,5-Trimethoxybenzyl 5-(4-chloro-2-nitrophenyl)-2-furoate (19). PyBOP (369 
mg, 0.71 mmol) was added as coupling reagent to a solution of 5-(4-chloro-2-
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nitrophenyl)-2-furoic acid (200 mg, 0.71 mmol) with TEA (164 µL, 1.19 mmol) in 
CH2Cl2 (10 mL) followed by 3,4,5-trimethoxybenzyl alcohol (101 µL, 0.61 mmol), and 
the resulting mixture was stirred at 25 ºC during 12 hours. The reaction mixture was 
evaporated in vacuo and the solid was purified by column cromatography on silica 
using hexane/ethyl acetate (6:1) as eluent to afford a white solid (130 mg, 38% yield). 
mp 147.3 ºC. 1H NMR (300 MHz, CDCl3): δ 8.37-7.87, 7.86, 7.30, 5.87, 4.48, 4.44. 13C 
NMR (75 MHz, CDCl3): δ 158.5, 153.8, 151.1, 148.4, 145.6, 138.5, 136.1, 132.8, 131.4, 
131.2, 124.9, 122.0, 124.8, 120.2, 112.2, 106.0, 67.4, 61.3, 56.6. MS (ES, [M+Na]+): m/ 
z = 470. Anal.C25H28O5 (C, H, O).  
3,4,5-Trimethoxybenzyl 5-(4-nitrophenyl)-2-furoate (21). PyBOP (509 mg, 0.98 
mmol) was added as coupling reagent to a solution of 5-(4-nitrophenyl)-2-furoic acid 
(200 mg, 0.82 mmol) with TEA (227 µL, 1.64 mmol) in CH2Cl2 (10 mL) followed by 
3,4,5-trimethoxybenzyl alcohol (168 µL, 0.98 mmol), and the resulting mixture was 
stirred at 25 ºC during 24 hours. The reaction mixture was evaporated in vacuo and the 
solid was purified by column cromatography on silica using hexane/ethyl acetate (4:1) 
as eluent to afford a white solid (34 mg, 10% yield). mp 161.2 ºC. 1H NMR (300 MHz, 
CDCl3): δ 7.52, 7.93, 7.31, 6.95, 6.69, 5.30, 3.93-3.86. 13C NMR (75 MHz, CDCl3): δ 
158.6, 155.4, 153.8, 147.9, 145.6, 143.2, 135.4, 131.4, 125.7, 124.8, 120.6, 110.5, 
106.3, 67.5, 61.3, 56.6. MS (ES, [M+Na]+): m/ z = 436. Anal. C21H19NO8 (C, H, N, O). 
3,4,5-Trimethoxybenzyl 5-(4-methyl-2-nitrophenyl)-2-furamide (31). PyBOP (618 
mg, 1.19 mmol) was added as coupling reagent to a solution of 5-(4-methyl-2-
nitrophenyl)-2-furoic acid (300 mg, 1.19 mmol) with TEA (274 µL, 1.98 mmol) in 
CH2Cl2 (10 mL) followed by 3,4,5-trimethoxybenzylamine (173 µL, 0.99 mmol), and 
the resulting mixture was stirred at 25 ºC during 12 hours. The reaction mixture was 
evaporated in vacuo and the solid was purified by column cromatography on silica 
Page 19 of 48
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
using hexane/ethyl acetate (3:1) as eluent to afford a yellow solid (56 mg, 14% yield). 
mp 114.2 ºC. 1H NMR (300 MHz, CDCl3): δ 7.49, 7.34, 7.15, 6.65, 6.51, 4.48, 3.81, 
3.75, 2.39. 13C NMR (75 MHz, CDCl3): δ 158.2, 153.9, 150.6, 148.4, 148.2, 141.1, 
137.3, 133.9, 133.2, 125.2, 124.8, 120.7, 116.6, 111.5, 105.1, 61.3, 56.6, 43.8, 21.5. MS 
(ES, [M+H]+): m/ z = 427. Anal. C22H22N2O7 (C, H, N, O). 
Radiometric phosphodiesterase inhibition assay. The methodology used for 
measuring human recombinant PDE7A1, PDE7B and PDE3A activity was based in a 
Scintillation Proximity Assay (SPA) from Perkin Elmer (TRKQ7090). The activity of 
the phosphodiesterase is measured by co-incubating the enzyme with [3H]cAMP and the 
hydrolysis of the nucleotide is quantified by radioactivity measurement after binding of 
[3H]AMP to scintillation binding bead. 
Either 0.02 units of PDE7A1 (Calbiochem # 524751), 0.02 units of PDE3A 
(Calbiochem # 524742) or 0.5 units of PDE7B (Abcam # ab79800) were incubated in a 
96-well flexiplate with 5 nCi of [3H]cAMP and inhibitors in 100 μL of assay buffer 
(contained in the kit) for 20 min at 30ºC. After the incubation time, 50µL of a solution 
of SPA-beads (approximately 1 mg per well) were added to each well and plate was 
shaken for 1 hour at room temperature. Finally, beads were settled for 30 min and 
radioactivity was detected in a Microbeta Trilux reader.  
IC50 values were calculated by non-linear regression fitting using GraphPad Prism. 
Data (radioactivity vs log concentration) was fitted to a sigmoidal dose-response 
equation: Y = Bottom + (Top-Bottom)/(1+10^((logIC50-X)*n)), where Bottom and Top 
were the minimum and maximal inhibition for PDE, respectively, IC50 was the 
concentration of compound that inhibited the PDE activity in a 50% and n was the slope 
of the concentration-response curve. 
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The mode of inhibitory action for compound 13 and 31 was determined by varying 
the concentration of unlabelled cAMP in the reaction cocktail within the range of 5nM 
to 2μM in the presence of a fixed concentration of [3H]-cAMP tracer and inhibitor 
concentrations. Enzyme activity data were analyzed using Lineweaver-Burk plots using 
GraphPad Prism. 
Fluorescence polarization phosphodiesterase inhibition assay. The ability of 
compounds to inhibit PDE4B2 (human recombinant) and PDE4D3 (human 
recombinant) was determined by IMAP Fluorescence Polarisation (FP) assay 
(Molecular Devices R8175).  
0.05U of PDE4B2 (Calbiochem # 524736), PDE4D3 (Calbiochem # 524733) were 
incubated in a 96-well black half-area plate with 1nM of Fluorescein adenosine 3′,5′-
cyclic phosphate (contained in the kit) and inhibitors in 40µL of assay buffer. Plates 
were mixed on a shaker for 10 seconds and incubated at ambient temperature for 60 
minutes. IMAP binding reagent was added (60 μL of a 1 in 600 dilution in binding 
buffer of the kit stock solution) to terminate the assay. Plates were allowed to stand at 
ambient temperature for 1 hour. The FP ratio was measured with a Tecan Ultra 
Evolution Reader.  
IC50 values were calculated by non-linear regression fitting using GraphPad Prism. 
Data (fluorescence polarization vs log concentration) was fitted to a sigmoidal dose-
response equation: Y = Bottom + (Top-Bottom)/(1+10^((logIC50-X)*n)), where Bottom 
and Top were the minimum and maximal inhibition for PDE, respectively, IC50 was the 
concentration of compound that inhibited the PDE activity in a 50% and n was the slope 
of the concentration-response curve. 
Molecular modeling. To carry out docking analysis, chain A of protein structures 
were processed with help of Sybyl8.0 software32 adding hydrogens, and capping 
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terminal residues with neutral ends. Then, newly added hydrogen positions were 
optimized with MMFF94 force field until a 0.01kcal/mol gradient was reached. Ligand 
geometries were also minimized with MMFF94 force field until a 0.01kcal/mol gradient 
was reached. 
The docking studies were performed with Surflex (Sybyl). An “Automatic” protocol 
was generated and dockings were carried out using 20 initial conformations for each 
ligand allowing flexibility. Pre and post minimization was used considering 100 
solutions in each case. Cscore scoring function was used with all the four options and 
claiming for a relaxed structure.  
Visual inspection of solutions of selected ligands was carried out in order to find 
which ones allow the best agreement with SAR data. Finally the selected ligand-
complex geometries were minimized with MMFF94 force field until a 0.01kcal/mol 
gradient was reached. 
To test our docking protocol and validate the procedure, we carried out docking 
experiments for some selected 3D structures The first one was for the complex of 3,5-
dimethyl-1-(3-nitrophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester bound to PDE4D 
(pdb code 1Y2K), as this ligand shares a high similarity with some of our inhibitors. 
The high similarity between the docked solution (only one cluster within 2.0Å rmsd of 
heavy atoms was found) and the experimental one gave us confidence in our protocol 
(rmsd 0.2Å of heavy atoms vs exp., see figure S2 in the supporting information). In fact, 
the main difference between both orientations is related with the benzene with supports 
a nitro group. This difference can be explained due to the lack of water W1016 from the 
pdb, which was not present in the model of PDE4D used for docking were only the 
metal coordination waters (W1003-W1008) were retained. On the other hand, in order 
to test our protocol specifically in PDE7, we carried out the docking experiment with 
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the 3D structures of pdb code 1ZKL and 3G3N. In the case of 1ZKL, the reproduction 
of the experimental binding mode of IBMX inhibitor was only possible (rmsd 0.1Å of 
heavy atoms vs exp., see figure S3 in the supporting information) when waters W573 
and W542 were added aside with the metal coordination waters (W504-W509). This 
fact is not surprising as those two additional water molecules are within 3.0Å from the 
ligand. As only those two structures of PDE7A were available at the moment of this 
study (pdb codes. 1ZKL, 3G3N), and given the redocking results obtained for 3G3N we 
decided to use structure 1ZKL for docking purposes. Finally, as the best redocking 
results were obtained for structure 1Y2K, which ligand is the most similar to our 
inhibitors, we decided to retain only the metal coordination waters present in pdb code 
1ZKL for docking. 
Primary cell cultures. Glial cells were prepared from neonatal rat cerebral cortex, as 
previously described by Luna-Medina et al.33 Briefly, after removal of the meninges the 
cerebral cortex was dissected, dissociated, and incubated with 0.25% trypsin/EDTA at 
37 ºC for 1 hour. After centrifugation, the pellet was washed 3 times with HBSS 
(Gibco) and the cells were plated on non-coated flasks and maintained in 
HAMS/DMEM (1:1) medium containing 10% FBS. After 15 days the flasks were 
agitated on an orbital shaker for 4 hours at 240 rpm at 37 ºC, the supernatant was 
collected, centrifuged, and the cellular pellet containing the microglial cells resuspended 
in complete medium (HAMS/DMEM (1:1) containing 10% FBS) and seeded on 
uncoated 96-well plates. Cells were allowed to adhere for 2 hours and the medium was 
removed to eliminate non-adherent oligodendrocytes. New fresh medium containing 10 
ng/mL of GM-CSF was added. The remaining astroglial cells adhered on the flasks 
were then trypsinized, collected, centrifugated and plated onto 96-well plates with 
complete medium. The purity of cultures obtained by this procedure was >98% as 
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determined by immunofluorescence with the OX42 (microglial marker) and the GFAP 
(astroglial marker) antibodies. After 1 week in culture, cells were treated with Rolipram, 
BRL50481 and the different compounds (7, 13, 14, 19, 21 and 31) at several 
concentrations. Cell viability was then measured after 16h in culture. For nitrite release 
quantification some cultures were also treated with lipopolysaccharide (LPS; 10µg/mL) 
alone or in combination with compounds.  
Cell viability assay. Cell viability was measured using the MTT assay from Roche, 
based on the ability of viable cells to reduce yellow MTT to blue formazan. Briefly, 
cells cultured in 96-well plates and treated with the indicated compounds for 16h were 
incubated with MTT (0.5mg/mL, 4h) and subsequently solubilized in 10% SDS/0.01M 
HCl for 12h in the dark. The extent of reduction of MTT was quantified by absorbance 
measurement at 595nm according to the manufacturer´s protocol. 
Nitrites measurement. Accumulation of nitrites in media was assayed by the 
standard Griess reaction. After stimulation of cells with the different compounds, 
supernatants were collected and mixed with an equal volume of Griess reagent (Sigma). 
Samples were then incubated at room temperature for 15 minutes and absorbance read 
using a plate reader at 492/540 nm. 
cAMP measurements in Raw cells. Quantification of cAMP was carried out using 
the EIA (enzyme immunoassay) kit from GE Healthcare. Briefly, Raw cells were 
seeded at 3x104/well in 96-well dishes and incubated overnight before the assay. After 
60 min incubation with compound 13, cAMP intracellular levels were determined 
following the manufacture’s instructions. 
CNS penetration: In vitro Parallel artificial membrane permeability assay 
(PAMPA)-Blood brain barrier (BBB). Prediction of the brain penetration was 
evaluated using a parallel artificial membrane permeability assay (PAMPA).30 Ten 
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commercial drugs, phosphate buffer saline solution at pH 7.4 (PBS), Ethanol and 
dodecane were purchased from Sigma, Acros organics, Merck, Aldrich and Fluka. The 
porcine polar brain lipid (PBL) (catalog no. 141101) was from Avanti Polar Lipids. The 
donor plate was a 96-well filtrate plate (Multiscreen® IP Sterile Plate PDVF membrane, 
pore size is 0.45 µM, catalog no. MAIPS4510) and the acceptor plate was an indented 
96-well plate (Multiscreen®, catalog no. MAMCS9610) both from Millipore. Filter 
PDVF membrane units (diameter 30 mm, pore size 0.45 μm) from Symta were used to 
filtered the samples. A 96-well plate UV reader (Thermoscientific, Multiskan spectrum) 
was used for the UV measurements. Test compounds [(3-5 mg of Caffeine, Enoxacine, 
Hydrocortisone, Desipramine, Ofloxacine, Piroxicam, Testosterone), (12 mg of 
Promazine) and 25 mg of Verapamile and Atenolol] were dissolved in EtOH (1000 µL). 
100 microlitres of this compound stock solution was taken and 1400 µL of EtOH and 
3500 µL of PBS pH 7.4 buffer were added to reach 30% of EtOH concentration in the 
experiment. These solutions were filtered. The acceptor 96-well microplate was filled 
with 180 μL of PBS/EtOH (70/30). The donor 96-well plate was coated with 4 µL of 
porcine brain lipid in dodecane (20 mg mL-1) and after 5 minutes, 180 μL of each 
compound solution was added. 1-2 mg of every compound to be determined their ability 
to pass the brain barrier were dissolved in 1500 µL of EtOH and 3500 µL of PBS pH 7.4 
buffer, filtered and then added to the donor 96-well plate. Then the donor plate was 
carefully put on the acceptor plate to form a “sandwich”, which was left undisturbed for 
2h and 30 min at 25 °C. During this time the compounds diffused from the donor plate 
through the brain lipid membrane into the acceptor plate. After incubation, the donor 
plate was removed. UV plate reader determined the concentration of compounds and 
commercial drugs in the acceptor and the donor wells. Every sample was analyzed at 
three to five wavelengths, in 3 wells and in two independent runs. Results are given as 
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the mean [standard deviation (SD)] and the average of the two runs is reported. 10 
quality control compounds (previously mentioned) of known BBB permeability were 
included in each experiment to validate the analysis set. 
EAE induction and treatment. Six-week-old female C57BL6 mice (15-20 g) were 
purchased from Harlan (Spain). All experimental procedures followed the European 
Communities Council Directive of November 24, 1986 (86/609/EEC). The protocol was 
approved by the ethic committee of the University of Barcelona and of the Generalitat 
de Catalunya. The mice were maintained on a 12h light/dark cycle at a constant 
environmental temperature with free access to food and water for 1 week prior to 
experimentation. 
EAE was induced by subcutaneous immunization with 100μg MOG35-55 peptide 
(EspiKem S.r.l., Italy) in 100μL complete Freund’s adjuvant (CFA) (Sigma-Aldrich) 
enriched with Mycobacterium tuberculosis (H37Ra strain, Difco, Detroit, MI, USA). 
Mice were immediately intraperitoneally injected with 200ng of Bordetella pertussis 
toxin (Sigma-Aldrich) and again 48h after the immunization.  
Animals (n=13) were weighed and examined for clinical signs on a daily basis. 
Disease severity of EAE was graded according to a five-point scale: Grade 0 = no 
disability; 1 = a flaccid tail; 2 = a mild but definite weakness of one or both hind legs; 3 
= moderate paraparesis of one hind leg; 4 = no hind leg movement; 5 = a moribund state 
with little or no spontaneous movement and impaired respiration.34 
Stock solution of the compound (100mg/mL in DMSO) was diluted 1:50 in a solution 
of 5% Tocrisolve (Tocris, UK) in distilled water. Mice were treated through daily 
intraperitoneal (i.p.) injection starting on day 5 after the onset of the disease at a dose of 
10 mg/kg of animal (n=7) or with only vehicle (n=7).  
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TABLES 
Table 1. PDE7A1 activities for derivatives 1-3.  
Compound  Chemical structure Experimental 
IC50 PDE7A1 (µM) 
 
 
1 
EtO
OEt
OEt
OO O
Me
NO2
 
 
0.58±0.0922 
 
 
2 
N
S NH
O
O
Me
EtO
O
O
N
H
O
 
 
 
0.86±0.0422 
 
 
3 
H
N
N
Me
O
O
Cl
Cl
Cl
 
 
 
0.88±0.1622 
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Table 2. PDE7A1 inhibition of compounds (5-32).  
Comp. %inh 
PDE7A1 
@10μM 
Comp. %inh 
PDE7A1 
@10μM 
5 24.4 ±13.4 19 49.1±9.5 
6 49.5 ±3.0 20 14.0±1.1 
7 48.8 ±11.1 21 48.0 ±7.7 
8 3.7 ± 2.0 22 14.0±7.8 
9 39.9 ±8.6 23 30.7±14.8 
10 16.4 ± 1.1 24 30.8±0.5 
11 10.0±6.9 25 31.1±8.7 
12 -9.9±1.5 26 29.2 ±0.2 
13 57.9±0.1 27 28.0±4.5 
14 54.9±3.6 28 44.8±1.2 
15 34.6±2.3 29 41.6±6.5 
16 38.3±7.8 30 23.5±0.4 
17 8.0±0.1 31 70.5±4.6  
18 28.8±0.2 32 -10.3±0.6 
 
Page 33 of 48
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Table 3. IC50 values for PDE7A1 of selected compounds and BRL50481 as standard 
reference.a 
Comp. 6 7 13 14 19 21 31 
PDE7A1 
IC50 
(µM) 
33.37±8.1 12.34±3.22 5.17±1.11 2.63± 0.92 7.31±3.57 14.07±2.9 3.20±1.23 
aIC50 (BRL50481) = 0.09 µM 
 
Table 4. PDE3A inhibition for selected compounds. 
Comp. %inh 
PDE3A 
@10μM 
IC50 
PDE3A 
(µM) 
Ratio 
PDE7A1
/PDE3A 
7 3.0±12.7 104.2±36.6 0.12 
13 46.1±3.0 54.6±12.1 0.09 
14 74.9±5.4 1.8±0.85 1.44 
19 11.0±4 n.d. n.d. 
21 57.1±12 3.4±1.3 4.15 
31 49.6±1.2 3.9±0.7 0.82 
 
 
Table 5. IC50 values (µM) on different PDEs for compound 13. 
Comp. PDE7A1 PDE7B PDE3A PDE4B2 PDE4D3 
13 5.1±1.11 23.2±4.4%@10µM 54.6±8.1 12.4±4.2 66.3±13.9 
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FIGURES 
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Figure 1. Studies of the PDE7A1 inhibition in the absence (control) and in the presence 
of two different concentrations of the furan derivatives 13 and 31 incubating different 
cAMP concentrations and measuring AMP formation. Data represent the mean±sem 
(vertical bars) of triplicate measurements. 
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Figure 2. Proposed binding mode for compound 13 (pdb code 1ZKL) showing relevant 
interactions with nearby residues. Distances are given in angstroms. 
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Figure 3. Proposed binding mode for compound 24 (for pdb code 1ZKL) showing 
relevant interactions with nearby residues. Distances are given in angstroms. 
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Figure 4. Proposed binding mode for compound 23 (pdb code 1ZKL) showing relevant 
interactions with nearby residues. Distances are given in angstroms. 
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Figure 5. Proposed binding mode for compound 31 (pdb code 1ZKL) showing relevant 
interactions with nearby residues. Distances in angstroms. 
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Figure 6. Cell viability and nitrite production. Glial cultures were treated during 16h 
with Rolipram (30 µM), BRL50481 (BRL; 30 µM) and compounds 7, 13, 14, 19, 21, 31 
(5 or 10 µM) and cell viability measured. Some cultures were treated with 
lipopolysaccharide (LPS), in presence or absence of compound at indicated 
concentrations, and the production of nitrites measured as indicated in the experimental 
section. Values represent the mean ± SD of six replications in three different 
experiments. *** p<0.001 versus LPS-treated cells. 
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Figure 7. Cell viability and nitrite production. Astrocytes cultures were treated 
during 16h with Rolipram (30 µM), BRL50481 (BRL; 30 µM) and compounds 7, 13, 
14, 19, 21, 31 (5 or 10 µM) and cell viability measured. Some cultures were treated with 
lipopolysaccharide (LPS) in presence or absence of compound at indicated 
concentrations, and the production of nitrites measured as indicated in the experimental 
section. Values represent the mean ± SD of six replications in three different 
experiments. *** p<0.001 versus LPS-treated cells. 
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Figure 8. Intracellular cAMP level in Raw cells treated with compound 13 at 30 and 10 
µM. 
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 Figure 9. Therapeutic effect of compound 13 in MOG35-55-induced EAE in C57BL6J 
mice. Fourteen C57BL6J mice immunized with MOG35-55 at 100 µg /mouse in the 
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presence of complete Freund’s adjuvant developed clinical signs on day 12. Animals 
were divided into two groups. One group was treated with compound 13 starting from 
day 5 after the onset of the disease (arrowhead) for 26 days. Mice in the control group 
were administered vehicle only. A) EAE scores in drug treatment; B) percentage of 
body weight variation. Results were expressed as the mean ± standard error of the mean 
and statistical differences in EAE scores between the vehicle and the treatment group 
was calculated by Mann-Whitney test (*p<0.0002). ●, Vehicle (n=7); ▲, 10 mg/kg 
compound 13 (n=7) i.p. daily. 
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SCHEMES 
Scheme 1a  
R1
R1
R1
O OH
O
R1
R1
R1
OO O
+
HO
R2
R2
aReagents: i) Coupling reagent, TEA, r.t., CH2Cl2
i
R2 = 4-Me
R2 = 2,4-diClR1 = OMe
R1 = OEt
R2 = 4-NO2
5
6
R2 = 2,4-diCl
R2 = 4-NO2
R2 = H 7
8
9
10
 
Page 45 of 48
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Scheme 2a 
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X O R3
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HO
O Oi
aReagents: i) PyBOP, TEA, r.t., CH2Cl2
X=O, R1=R2 = OMe R3 = H
R3 = Me
R3 = Ph
R3 = 2-CF3-Ph
R3 = 2-Cl-Ph
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CHARTS 
 
 
 
 
Chart 1. Pharmacophore features and their angles and distances relation (Å). 
OEt
EtO OEt
OO O
Me
NO2
 
Chart 2. Selected lead compound 1 for further optimization and areas where 
modifications have been done. 
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